Two innovations concerning the treatment of serious neuromuscular diseases (Amyotrophic Lateral Sclerosis and Duchenne Muscular Dystrophy) are presented by the Chief Medical Officer of the Italfarmaco Group, Paolo Bettica. The event offers the opportunity for the Group CEO, Paolo Zambonardi, to underline that these results are the effect of a flexible and articulated business strategy, based on sectors of business activity, apparently irreconcilable but in reality synergistic: basic research and “incremental innovation”.